作者: Yvonne Buggy , Victoria Cornelius , Lynda Wilton , Saad A.W. Shakir
DOI: 10.2165/11588510-000000000-00000
关键词:
摘要: Background: Marketing authorization for rimonabant was withdrawn in October 2008, mainly because the psychiatric adverse effects could not be addressed by further risk minimization.